<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175522</url>
  </required_header>
  <id_info>
    <org_study_id>GC5107AE01</org_study_id>
    <nct_id>NCT04175522</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:</brief_title>
  <official_title>A Phase 2a, Prospective, Open-label, Single-arm, Single Center, Proof of Concept Study to Evaluate the Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of IGIV 10% in patients with
      autoimmune encephalitis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Actual">June 11, 2020</completion_date>
  <primary_completion_date type="Actual">June 11, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chage of mRS(The Modified Rankin Scale) score; 0(better) to 6(worse)</measure>
    <time_frame>28 days</time_frame>
    <description>Change of mRS score 7 days and 28 days after IP administration compared with baseline(before IP administration)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chage and improvement of mRS(The Modified Rankin Scale) score; 0(better) to 6(worse)</measure>
    <time_frame>28 days</time_frame>
    <description>Change and improvment of mRS score 14 days and 28 days after IP administration compared with baseline(before IP administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chage and improvement of Glasgow coma scale(GCS); 3(worse) to 15(better)</measure>
    <time_frame>28 days</time_frame>
    <description>Change and improvment of Glasgow coma scale(GCS) 7 days, 14 days and 28 days after IP administration compared with baseline(before IP administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chage and improvement of Clinical Global Impression Scale-Severity; 1(better) to 7(worse)</measure>
    <time_frame>28 days</time_frame>
    <description>Change and improvment of Clinical Global Impression Scale-Severity 7 days, 14 days and 28 days after IP administration compared with baseline(before IP administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chage and improvement of Clinical Global Impression Scale-Impovement; 1(better) to 7(worse)</measure>
    <time_frame>28 days</time_frame>
    <description>Change and improvment of Clinical Global Impression Scale-Improvement 7 days, 14 days and 28 days after IP administration compared with baseline(before IP administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chage and improvement of CASE(Clinical Assessment scale of Encephalitis) score; 0(better) to 27(worse)</measure>
    <time_frame>28 days</time_frame>
    <description>Change and improvment of CASE score 7 days, 14 days and 28 days after IP administration compared with baseline(before IP administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship</measure>
    <time_frame>28 days</time_frame>
    <description>The relationship between neurological scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Autoimmune Encephalitis</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational product(IP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunoglobulin G</intervention_name>
    <description>IGIV 10%(400mg/kg) QD for 5 consecutive days administrated intravenously.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, aged more than 12 years.(adolescent or adult)

          2. Subject who all three of the following diagnosis criteria for possible autoimmune
             encephalitis have been met.

               -  Subacute onset (rapid progression of less than 3 months) of working memory
                  deficits(short-term memory loss), altered mental status, or psychiatric symptoms.

               -  At least one of the following:

                    -  New focal CNS findings

                    -  Seizure not explained by a previously known seizure disorder

                    -  CSF pleocytosis (WBC count ≥ 5/mm2)

                    -  MRI features suggestive of encephalitis

               -  Reasonable exclusion of alternative causes

          3. Subjects or parent/legal representative willing to provide written informed consent

        Exclusion Criteria:

          1. Subject who has received Immunoglobulin therapy within 10 weeks prior to screening

          2. Subject who has a history of hypersensitivity or shock to ingredient of immunoglobulin

          3. Subject who has been diagnosed with IgA deficiency

          4. Subject who has renal disorder (creatinine clearance &lt; 10 ml/min) or requires dialysis

          5. Subject who has been diagnosed with hemolytic anemia or anemia from blood loss

          6. Subject who has been diagnosed with immuonological competence or immunodeficiency

          7. Subject who has high risk of thrombus or embolism (History of thrombus/embolism or
             cerebro/cardiovascular disorder within 3 months prior to screening)

          8. Subject who has low heart condition (Congestive heart failure &gt;NYHA functional class
             Ⅱ: unstable coronary artery disease or myocardiac infarction within 3 months prior to
             screening)

          9. Subject who cannot prohibit the previously administrated steroids by investigator's
             discretion (ex. Suspicion of steroid dependence, hypoadrenocorticism, when treatment
             effects are expected, etc.)

         10. Females who are pregnant or breast feeding

         11. Subject who is considered by investigator to ineligible for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soon Tae Lee, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 21, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>June 28, 2020</last_update_submitted>
  <last_update_submitted_qc>June 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hashimoto Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

